These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 18408619

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Exercise training attenuates acute doxorubicin-induced cardiac dysfunction.
    Chicco AJ, Schneider CM, Hayward R.
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):182-9. PubMed ID: 16495754
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Exercise preconditioning provides long-term protection against early chronic doxorubicin cardiotoxicity.
    Hydock DS, Lien CY, Jensen BT, Schneider CM, Hayward R.
    Integr Cancer Ther; 2011 Mar; 10(1):47-57. PubMed ID: 21382960
    [Abstract] [Full Text] [Related]

  • 7. Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity.
    Chicco AJ, Hydock DS, Schneider CM, Hayward R.
    J Appl Physiol (1985); 2006 Feb; 100(2):519-27. PubMed ID: 16210442
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.
    de Beer EL, Bottone AE, van Rijk MC, van der Velden J, Voest EE.
    Br J Pharmacol; 2002 Apr; 135(7):1707-14. PubMed ID: 11934811
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Doxorubicin-induced vascular dysfunction and its attenuation by exercise preconditioning.
    Gibson NM, Greufe SE, Hydock DS, Hayward R.
    J Cardiovasc Pharmacol; 2013 Oct; 62(4):355-60. PubMed ID: 23719093
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
    Saad SY, Najjar TA, Alashari M.
    J Biochem Mol Toxicol; 2004 Oct; 18(2):78-86. PubMed ID: 15122649
    [Abstract] [Full Text] [Related]

  • 18. Exercise training in doxorubicin-induced heart failure: effects on the L-arginine-NO pathway and vascular reactivity.
    Matsuura C, Brunini TM, Carvalho LC, Resende AC, Carvalho JJ, de Castro JP, Mendes-Ribeiro AC.
    J Am Soc Hypertens; 2010 Oct; 4(1):7-13. PubMed ID: 20374946
    [Abstract] [Full Text] [Related]

  • 19. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
    Bruynzeel AM, Mul PP, Berkhof J, Bast A, Niessen HW, van der Vijgh WJ.
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.